CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...
The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...
CRISPR-Cas9 is one of the biggest discoveries of the 21st century. Since it was developed in 2012, this gene-editing tool has revolutionized biology research, making it easier to study disease and ...
In this installment, we delve into one of the most debated scientific advancements of our time: CRISPR gene-editing ...
CRISPR gene-editing technology presents a possible solution for feeding a growing population, but incorporating CRISPR into ...
Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal ...
Researchers have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal neurodegenerative condition. The treatment, which uses ...
ON CRISPR enzyme, will combine with RNA guides for pharma customers. Deal follows HuidaGene agreement, offers 99% cost ...
Finding out your dog’s breed can be a fun experience, but there are also plenty of reasons to get a dog DNA kit that will have an impact on your furry friend’s wellbeing. Identifying genetic ...
Synthego granted global license to manufacture and distribute AZ's CRISPR gene editing enzyme, eSpOT-ON.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback